How is a GHK-Cu and KPV blend dosed and mixed?
Draw to
unitsmL
0.3 mL · 30 units syringe0.5 mL · 50 units syringe1 mL · 100 units syringe3 mL · 3cc syringe0.5 mL · 20 units, U-40 syringe1 mL · 40 units, U-40 syringe
Concentration is the powder in the vial divided by the water. The draw is the dose divided by the concentration, in mL, times 100 on a U-100 syringe or 40 on a U-40. Every figure comes from what you enter.
Save to Milligram
Open in Milligram shows once the calculator has a result.
Open in Milligram is off while the dose is more than the whole vial. Check the dose and its unit.
Open in Milligram is off while the draw is under one unit. Check the dose and its unit.
Open in Milligram adds KPV and this dose to a plan in the app, with the schedule you pick here. The vial and water are not saved.
Searches of DailyMed, ClinicalTrials.gov and PubMed found no label or human trial dose for a GHK-Cu and KPV blend; of the people logging KPV in Milligram, 43% logged 500 mcg, the KPV dose logged most often.11
Every vial at a glance. Pick a cell to draw it on the syringe.
| Vial | 1 mL of water | 2 mL of water | 3 mL of water |
|---|---|---|---|
| 10 mg | 10 mg/mL: 250 mcg is 2.5 units, 500 mcg is 5 units | 5 mg/mL: 250 mcg is 5 units, 500 mcg is 10 units | 3.333 mg/mL: 250 mcg is 7.5 units, 500 mcg is 15 units |
Vial strengths, water and syringe marks
Vendor pages list the blend, for research use only, as lyophilized powder, 50 mg GHK-Cu with 10 mg KPV in a 3 ml vial, or 50 mg GHK-Cu with 20 mg KPV.12 Searches of DailyMed and maker pages found no mixing instructions for the blend; the general steps are in the mixing guide. Of the people who logged KPV, 84% set up a 10 mg vial and 47% set up 10 mg with 2 mL, and 18% logged 500 mcg at 10 units.11 The syringe and calculator below are for that KPV-only vial and mix, not the blend: 10 mg in 2 mL is 5 mg per mL, so 500 mcg is 0.1 mL, the 10 unit mark on a U-100 syringe. In the vendor vial of 50 mg GHK-Cu with 10 mg KPV, 2 mL also gives KPV at 5 mg per mL, so the same 10 unit mark holds 500 mcg KPV with 2.5 mg GHK-Cu.1
The calculator is at the top of the page
Dose and schedule
Searches of DailyMed found no label dose for the blend, for injected GHK-Cu or for KPV, and searches of ClinicalTrials.gov and PubMed found no human trial dose for any of them. The only injected figures the searches found are in a GHK review: its authors estimate, from their animal injection studies, that about 100-200 mgs of GHK will produce therapeutic actions in humans, adding that even this may overestimate the dose, and they scale a rat bone-fracture study of a mixture of GHK, dalargin and thymogen to about 140 micrograms of total peptide per injection with treatments for 10 days.3 The human trials of GHK-Cu the searches found are topical: the CuHeal phase 2 trial (NCT07437586, still recruiting, an estimated 60 healthy adults) gives each person two small punch-biopsy wounds on the upper arm, with 0.1% w/w GHK-Cu gel applied once daily for 14 days to one and a vehicle gel to the other.4 In a venous ulcer trial with Eighty-six evaluable patients, silver sulfadiazine 1% cream reduced ulcer size more than a 0.4% tripeptide copper complex cream or placebo, and in a trial after CO2 laser resurfacing, patients rated skin quality higher with GHK-Cu products (P = .04) while objective evaluation found no significant improvement; that report gives no dose or group size.56 For KPV, searches of ClinicalTrials.gov and PubMed returned no human trial, and the saved studies are in mice and cells, including a study that gave mice oral KPV at 100 μM, added to the drinking water, in a colitis model.7
Of the people who logged KPV, 43% logged 500 mcg, 17% logged 250 mcg, 96% logged the route as under the skin and 65% also logged GHK-Cu; of the people who logged GHK-Cu, 13% also logged KPV.11 Searches of trial registries and PubMed found no human schedule or cycle length for injected use; the only length found is the 10 days in the review's figure scaled from rats.3
Label status and storage
Searches of DailyMed found no label for KPV or for any blend of the two peptides. A law-firm summary of FDA's notice says GHK-Cu was removed from Category 1 after its nomination was withdrawn, with an advisory committee consultation planned before the end of February 2027.8 FDA's compounding page says it has found no human exposure data on drug products containing KPV by any route.9 It adds that compounded injectable GHK-Cu may carry an immunogenicity risk and that human data are limited.9 One vendor page says to store its blend vial in a cool, dry place away from direct light, with no temperature or time, and searches of DailyMed, maker pages, PubMed and two reviews found no storage conditions for the blend after mixing.2
Frequently asked questions
Do dietary copper limits apply to injected GHK-Cu?
A GHK-Cu review gives 5 mg/day as the total oral intake in adults at which EFSA expects no copper retention and 10 mg/day as the US adult tolerable upper intake level, and says these dietary values cannot be converted directly into limits for injection.10
Is GHK-Cu a validated drug?
A GHK-Cu review says that, until controlled clinical efficacy is demonstrated, GHK-Cu is a promising but unproven therapeutic cargo rather than a clinically validated regenerative drug.10
How the logged figures are counted
Milligram app dose logs, aggregated and anonymous, the 90 days to 17 November 2026. Each figure is a share of people who set up or logged the item, and each share is of at least 50 people.
References
- Apex Amino. GHK-Cu/KPV Blend – 50mg/10mg – Apex Amino. 2026. apexamino.com
- Ameano Peptides. Beauty Blend (GHK-Cu/KPV) 50mg/20mg | Research Use Only. 2026. ameanopeptides.com
- BioMed Research International (full text, PubMed Central). GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. 2015. pmc.ncbi.nlm.nih.gov
- ClinicalTrials.gov. NCT07437586: Topical GHK-Cu Gel for Acute Skin Wound Healing. 2026. clinicaltrials.gov
- Journal of vascular surgery (PubMed abstract). A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers. 1992. pubmed.ncbi.nlm.nih.gov
- Archives of facial plastic surgery (PubMed abstract). Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. 2006. pubmed.ncbi.nlm.nih.gov
- Gastroenterology (full text, PubMed Central). PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation (mouse and cell study). 2008. pmc.ncbi.nlm.nih.gov
- Orrick. FDA Announces Removal of 12 Peptides from Category 2 and Schedules PCAC Meetings to Consider Adding Peptides to 503A Bulk Drug Substances List. 2026. orrick.com
- FDA. Substances in Compounding that May Present Significant Safety Risks. 2026. fda.gov
- Pharmaceutics (full text, PubMed Central). GHK-Cu as a Bioactive Metallopeptide and Drug-Delivery Cargo: Coordination Chemistry, Formulation Science, Therapeutic Evidence, and a Translational Roadmap. 2026. pmc.ncbi.nlm.nih.gov
- Milligram app dose logs, aggregated and anonymous, the 90 days to 17 November 2026. Each figure is a share of people who set up or logged the item, and each share is of at least 50 people. How these figures are counted